Search | VHL Search Portal

1.

NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.

Flaig, Thomas W; Spiess, Philippe E; Abern, Michael; Agarwal, Neeraj; Bangs, Rick; Buyyounouski, Mark K; Chan, Kevin; Chang, Sam S; Chang, Paul; Friedlander, Terence; Greenberg, Richard E; Guru, Khurshid A; Herr, Harry W; Hoffman-Censits, Jean; Kaimakliotis, Hristos; Kishan, Amar U; Kundu, Shilajit; Lele, Subodh M; Mamtani, Ronac; Mian, Omar Y; Michalski, Jeff; Montgomery, Jeffrey S; Parikh, Mamta; Patterson, Anthony; Peyton, Charles; Plimack, Elizabeth R; Preston, Mark A; Richards, Kyle; Sexton, Wade J; Siefker-Radtke, Arlene O; Stewart, Tyler; Sundi, Debasish; Tollefson, Matthew; Tward, Jonathan; Wright, Jonathan L; Cassara, Carly J; Gurski, Lisa A.

J Natl Compr Canc Netw ; 22(4): 216-225, 2024 05.

Article in English | MEDLINE | ID: mdl-38754471

2.

BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.

Sun, Steven H; Angell, Colin D; Savardekar, Himanshu; Sundi, Debasish; Abood, David; Benner, Brooke; DiVincenzo, Mallory J; Duggan, Megan; Choueiry, Fouad; Mace, Thomas; Trikha, Prashant; Lapurga, Gabriella; Johnson, Courtney; Carlson, Erick J; Chung, Catherine; Peterson, Blake R; Zhao, Jing; Kendra, Kari L; Carson, William E.

Cancer Immunol Immunother ; 72(11): 3461-3474, 2023 Nov.

Article in English | MEDLINE | ID: mdl-37528320

3.

Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.

Wilkins, Lamont J; Tosoian, Jeffrey J; Reichard, Chad A; Sundi, Debasish; Ranasinghe, Weranja; Alam, Ridwan; Schwen, Zeyad; Reddy, Chandana; Allaf, Mohammed; Davis, John W; Chapin, Brian F; Ross, Ashley E; Klein, Eric A; Nyame, Yaw A.

Cancer ; 127(9): 1425-1431, 2021 05 01.

Article in English | MEDLINE | ID: mdl-33721334

4.

Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.

Ranasinghe, Weranja; Reichard, Chad A; Nyame, Yaw A; Sundi, Debasish; Tosoian, Jeffrey J; Wilkins, Lamont; Alam, Ridwan; Achim, Mary F; Wang, Xuemei; Stephenson, Andrew J; Klein, Eric A; Ross, Ashley E; Allaf, Mohamad E; Davis, John W; Chapin, Brian F.

J Urol ; 204(4): 748-753, 2020 10.

Article in English | MEDLINE | ID: mdl-32259468

5.

Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.

Sundi, Debasish; Tosoian, Jeffrey J; Nyame, Yaw A; Alam, Ridwan; Achim, Mary; Reichard, Chad A; Li, Jianbo; Wilkins, Lamont; Schwen, Zeyad; Han, Misop; Davis, John W; Klein, Eric A; Schaeffer, Edward M; Stephenson, Andrew J; Ross, Ashley E; Chapin, Brian F.

Cancer ; 125(3): 391-397, 2019 02 01.

Article in English | MEDLINE | ID: mdl-30423193

6.

Editorial Comment.

Sundi, Debasish.

J Urol ; 211(4): 574, 2024 Apr.

Article in English | MEDLINE | ID: mdl-38241206

7.

Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?

Reichard, Chad A; Nyame, Yaw A; Sundi, Debasish; Tosoian, Jeffrey; Wilkins, Lamont; Alam, Ridwan; Achim, Mary F; Wang, Xuemei; Stephenson, Andrew J; Klein, Eric A; Ross, Ashley E; Davis, John W; Chapin, Brian F.

BJU Int ; 124(2): 282-289, 2019 08.

Article in English | MEDLINE | ID: mdl-30653804

8.

Editorial Comment.

Ray, Shagnik; Sundi, Debasish.

J Urol ; 208(3): 597, 2022 09.

Article in English | MEDLINE | ID: mdl-35892273

9.

Editorial Comment.

Schafer, Johanna M; Sundi, Debasish.

J Urol ; 208(4): 829, 2022 10.

Article in English | MEDLINE | ID: mdl-35830560

10.

Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.

Maurice, Matthew J; Sundi, Debasish; Schaeffer, Edward M; Abouassaly, Robert.

J Urol ; 197(3 Pt 1): 627-631, 2017 03.

Article in English | MEDLINE | ID: mdl-27582435

11.

Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience.

Sundi, Debasish; Cohen, Jason E; Cole, Alexander P; Neuman, Brian P; Cooper, John; Faisal, Farzana A; Ross, Ashley E; Schaeffer, Edward M.

Prostate ; 75(2): 191-9, 2015 Feb.

Article in English | MEDLINE | ID: mdl-25307625

12.

Identification of men with the highest risk of early disease recurrence after radical prostatectomy.

Sundi, Debasish; Wang, Vinson; Pierorazio, Phillip M; Han, Misop; Partin, Alan W; Tran, Phuoc T; Ross, Ashley E; Bivalacqua, Trinity J.

Prostate ; 74(6): 628-36, 2014 May.

Article in English | MEDLINE | ID: mdl-24453066

13.

Editorial Comment.

Sundi, Debasish; Nyame, Yaw A.

J Urol ; 202(2): 254-255, 2019 08.

Article in English | MEDLINE | ID: mdl-31107157

14.

Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.

Sundi, Debasish; Kryvenko, Oleksandr N; Carter, H Ballentine; Ross, Ashley E; Epstein, Jonathan I; Schaeffer, Edward M.

J Urol ; 191(1): 60-7, 2014 Jan.

Article in English | MEDLINE | ID: mdl-23770146

15.

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Faisal, Farzana A; Sundi, Debasish; Pierorazio, Phillip M; Ball, Mark W; Humphreys, Elizabeth B; Han, Misop; Epstein, Jonathan I; Partin, Alan W; Carter, H Ballentine; Bivalacqua, Trinity J; Schaeffer, Edward M; Ross, Ashley E.

BJU Int ; 114(6b): E120-E129, 2014 Dec.

Article in English | MEDLINE | ID: mdl-24731026

16.

Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.

Verma, Shiv; Swain, Diya; Kushwaha, Prem Prakash; Brahmbhatt, Smit; Gupta, Karishma; Sundi, Debasish; Gupta, Sanjay.

Cancers (Basel) ; 16(2)2024 Jan 05.

Article in English | MEDLINE | ID: mdl-38254738

17.

A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines.

Patel, Dixita M; Mateen, Ruba; Qaddour, Noor; Carrillo, Alessandra; Verschraegen, Claire; Yang, Yuanquan; Li, Zihai; Sundi, Debasish; Mortazavi, Amir; Collier, Katharine A.

Cancers (Basel) ; 16(2)2024 Jan 12.

Article in English | MEDLINE | ID: mdl-38254823

18.

Roles of Androgen Receptor Signaling in Urothelial Carcinoma.

Sundi, Debasish; Collier, Katharine A; Yang, Yuanquan; Diaz, Dayssy Alexandra; Pohar, Kamal S; Singer, Eric A; Gupta, Sanjay; Carson, William E; Clinton, Steven K; Li, Zihai; Messing, Edward M.

Cancers (Basel) ; 16(4)2024 Feb 10.

Article in English | MEDLINE | ID: mdl-38398136

19.

Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.

Purdue, Mark P; Dutta, Diptavo; Machiela, Mitchell J; Gorman, Bryan R; Winter, Timothy; Okuhara, Dayne; Cleland, Sara; Ferreiro-Iglesias, Aida; Scheet, Paul; Liu, Aoxing; Wu, Chao; Antwi, Samuel O; Larkin, James; Zequi, Stênio C; Sun, Maxine; Hikino, Keiko; Hajiran, Ali; Lawson, Keith A; Cárcano, Flavio; Blanchet, Odile; Shuch, Brian; Nepple, Kenneth G; Margue, Gaëlle; Sundi, Debasish; Diver, W Ryan; Folgueira, Maria A A K; van Bokhoven, Adrie; Neffa, Florencia; Brown, Kevin M; Hofmann, Jonathan N; Rhee, Jongeun; Yeager, Meredith; Cole, Nathan R; Hicks, Belynda D; Manning, Michelle R; Hutchinson, Amy A; Rothman, Nathaniel; Huang, Wen-Yi; Linehan, W Marston; Lori, Adriana; Ferragu, Matthieu; Zidane-Marinnes, Merzouka; Serrano, Sérgio V; Magnabosco, Wesley J; Vilas, Ana; Decia, Ricardo; Carusso, Florencia; Graham, Laura S; Anderson, Kyra; Bilen, Mehmet A.

Nat Genet ; 56(5): 809-818, 2024 May.

Article in English | MEDLINE | ID: mdl-38671320

20.

Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.

Chandra, Michael; Li, Roger; Parwani, Anil; Carson, William E; Pohar, Kamal; Sundi, Debasish.

Urol Oncol ; 41(9): 390.e1-390.e17, 2023 09.

Article in English | MEDLINE | ID: mdl-37061453

VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export:

NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.

BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.

Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.

Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.

Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.

Editorial Comment.

Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?

Editorial Comment.

Editorial Comment.

Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.

Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience.

Identification of men with the highest risk of early disease recurrence after radical prostatectomy.

Editorial Comment.

Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.

A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines.

Roles of Androgen Receptor Signaling in Urothelial Carcinoma.

Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.

Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.